300138 晨光生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入5,047,254-3.41%6,994,1936,871,5156,295,8734,873,610
减:营业总成本4,718,061-7.98%6,868,0456,450,8135,838,5774,525,723
    其中:营业成本4,316,380-10.82%6,437,2976,073,5995,418,1474,154,527
               财务费用40,497-24.91%72,26747,35422,74250,789
               资产减值损失(24,896)-69.89%(95,164)4,056(31,224)(25,950)
公允价值变动收益4,168271.68%(5,111)5,363(5,024)564
投资收益31,940339.22%17,78768,65138,47630,369
    其中:对联营企业和合营企业的投资收益16,24762.20%8,61613,12020,33617,954
营业利润368,695511.83%106,036548,325487,010384,869
利润总额370,347398.09%106,945555,819501,756398,066
减:所得税费用59,018102.72%28,98861,64565,67147,467
净利润311,329588.17%77,957494,173436,085350,599
减:非控股权益7,500-143.19%(16,093)14,4512,052(916)
股东净利润303,829385.30%94,050479,722434,033351,514

市场价值指针
每股收益 (元) *0.630425.00%0.1820.9020.8150.665
每股派息 (元) *----0.1300.1300.1600.130
每股净资产 (元) *6.90219.98%6.4376.5145.9405.228
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容